Posted on July 9, 2008 at 2:47 PM
Filed under: Corporate Strategy | Divesting and Restructuring
Tagged: Angiotech , AstraZeneca , GlaxoSmithKline , spin out strategy , spinout

[ Share ]  [ E-mail ]  [ Leave a Comment ]

We've been writing over the past week about how companies seem to be spinning out products or businesses with increasing frequency. Well, we've got another deal to toss in the load. As the folks over at Deal Journal report, GlaxoSmithKline plc is considering spinning off some of its early-stage drugs into a separate company.

The spinout strategy seems particularly attractive to drug companies. In February, pharmaceutical company AstraZeneca plc spun out its gastrointestinal disorders unit into a new company called Alberio Pharma, and on July 8, Angiotech Pharmaceuticals Inc. spun out its medical products division into a venture- and private equity-backed subsidiary. - Suzanne Stevens



Join Corporate Dealmaker's LinkedIn forum

Also From Corporate Dealmaker

• Deal Economy 2010: Morgan Stanley's Smith Barney integration
• JDA waits out storm for i2 buy
• Deal Economy 2010: Cisco's Hooper on M&A strategy
• GlobalLogic adds seasoned dealmaker
• Dell drives in IT services as PC slump deepens

Corporate Dealmaker Home Page

From TheDeal.com

• Tesla ready to drive to public market?
• Deal Economy 2010: IBM's Mendoza on using i-bankers
• Deal Economy 2010: Morgan Stanley's Smith Barney integration
• Peet's raises ante for Diedrich
• Deal Economy 2010: Cisco's Hooper on M&A strategy

TheDeal.com Home

Post a comment

Name:

Email Address:

URL:

Remember personal info?

Comments: (you may use HTML tags for style)

Please only click "Post" once. It may take a few moments to process.